Reuters logo
BRIEF-Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab
April 10, 2017 / 8:15 PM / 5 months ago

BRIEF-Five Prime Therapeutics announces completion of enrollment for the phase 2 of the ongoing trial of Cabiralizumab

April 10 (Reuters) - Five Prime Therapeutics Inc:

* Five Prime Therapeutics announces completion of enrollment for the phase 2 part of the ongoing trial of cabiralizumab for the treatment of pigmented villonodular synovitis (PVNS)

* Five Prime Therapeutics Inc - Five Prime plans to seek regulatory feedback on design of a pivotal trial

* Five Prime Therapeutics - plans to present initial data from phase 2 part of trial at 2017 American Society Of Clinical Oncology (ASCO) annual meeting Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below